IGFBP7 Secreted by Senescent Cells Suppresses the Benefits of Exercise

Key Takeaways

• IGFBP7 levels predict exercise fitness gains
• Deleting IGFBP7 boosts training response in mice
• Overexpressing IGFBP7 blocks exercise benefits
• Lower IGFBP7 associates with reduced mortality
• Senescent cell clearance may improve exercise outcomes

Summary

Researchers identified insulin‑like growth factor binding protein‑7 (IGFBP7) as a circulating factor that limits exercise adaptation in older adults. Plasma proteomics from a year‑long high‑intensity interval training trial showed higher IGFBP7 levels predicted smaller fitness gains. In mice, genetic deletion of Igfbp7 amplified training‑induced endurance, while overexpression eliminated the benefit. Lower IGFBP7 concentrations in the UK Biobank correlated with reduced mortality and fewer age‑related diseases, linking the protein to broader health outcomes.

Pulse Analysis

The study spotlights insulin‑like growth factor binding protein‑7 (IGFBP7) as a previously unappreciated component of the senescence‑associated secretory phenotype that circulates in older adults. Proteomic analysis of participants in a year‑long high‑intensity interval training (HIIT) trial showed that higher baseline plasma IGFBP7 correlated with smaller improvements in VO₂max, despite comparable starting fitness. Parallel mouse experiments confirmed causality: germline knockout of Igfbp7 amplified gains in treadmill endurance across multiple training regimens, while somatic overexpression erased the advantage. These data position IGFBP7 as a molecular brake on physiological plasticity.

The findings have immediate relevance for exercise prescription and the emerging field of senolytic therapies. If circulating IGFBP7 limits trainability, measuring its level could help identify individuals who will benefit most from conventional training versus those who may require adjunctive senescent‑cell clearance. Early‑phase trials of senolytics have already demonstrated improved muscle function in aged rodents; combining such agents with structured HIIT could unlock synergistic gains. Moreover, the IGFBP7 axis offers a druggable target—antibodies or small‑molecule inhibitors might transiently lower its activity during training windows, enhancing adaptation without wholesale cell removal.

Beyond performance, lower IGFBP7 concentrations were linked to reduced all‑cause mortality and fewer age‑related diseases in the UK Biobank, echoing the well‑established connection between cardiorespiratory fitness and healthspan. This convergence suggests that IGFBP7 not only curtails exercise benefits but also reflects broader systemic aging processes. Future research should map the downstream pathways through which IGFBP7 interferes with muscle remodeling, mitochondrial biogenesis, and inflammatory signaling. As the biotech industry pivots toward precision longevity interventions, IGFBP7 stands out as a biomarker and therapeutic foothold for extending functional capacity in the aging population.